Soligenix publishes data on ricin, anthrax test vaccines

Biopharmaceutical company Soligenix published data Monday demonstrating that the combination of the company's RiVax and VeloThrax candidate vaccines induced protective immunity to both ricin and anthrax toxins in animal studies.

“We are pleased that we have been able to show that a multivalent vaccine for both anthrax and ricin is feasible,” Soligenix President and CEO Christopher Schaber said. “The demonstration of simultaneous immunity to ricin and anthrax toxin is a step toward vaccines that can be used in the event of a national emergency.”

RiVax, Soligenix's vaccine candidate for the prevention of exposure to ricin toxin, is made using an antigen that does not contain the toxic elements of the substance. The company's vaccine candidate against anthrax, ThermoVax, uses a derivative of recombinant protective antigen that is being considered for inclusion in a next-generation anthrax vaccine.

"We are continuing to develop RiVax using ThermoVax, our proprietary vaccine thermostabilization technology for the stockpiling and distribution of vaccines outside of normal cold-chain requirements, under a recent NIAID contract award of up to $24.7 million over five years,” Schaber said. “Ultimately, we intend to develop the combination vaccine using this same technology."